SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
AbstractAimsThere is concern about the infection-related safety profile of sodium–glucose co-transporter 2 (SGLT-2) inhibitors. We aimed to determine the effect of SGLT-2 inhibitors on genitourinary and other infections via systematic review and meta-analysis of randomized controlled trials (RCTs). MethodsWe conducted a systematic search of Medline, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov to identify double-blinded RCTs enrolling ≥ 50 patients with type 2 diabetes which compared an SGLT-2 inhibitor to placebo or active comparator. Two independent reviewers extracted data and appraised study quality. Data were pooled using random-effects models. ResultsEighty-six RCTs enrolling 50,880 patients were included. SGLT-2 inhibitors increased the risk of genital infections compared to placebo (relative risk [RR] 3.37, 95% CI 2.89–3.93, I2 0%) and active comparator (RR 3.89, 95% CI 3.14–4.82, I2 0.3%). The risk of urinary tract infection (UTI) was not increased with SGLT-2 inhibitors compared to placebo (RR 1.03, 95% CI 0.96–1.11, I2 0%) or active comparator (RR 1.08, 95% CI 0.93–1.25, I2 22%). In drug-specific analyses, only dapagliflozin 10 mg daily was associated with a significantly increased risk of UTI compared to placebo (RR 1.33, 95% CI 1.10–1.61, I2 0%). SGLT-2 inhibitors were associated with a reduced risk of gastroenteritis (RR 0.38, 95% CI 0.20–0.72, I2 0%) but did not affect the risk of respiratory tract infections.Conclusions/interpretationSGLT-2 inhibitors are associated with an increased risk of genital tract infections. Although there is no association overall between SGLT-2 inhibitors and UTI, higher doses of dapagliflozin are associated with an increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“This advisory demonstrates the importance of adverse event monitoring in detecting rare but potentially serious complications of therapy, which may only be revealed upon widespread administration of the medication outside clinical trials [18].”
BackgroundMeta-analysis: Its strengths and limitations
WALKER, E., HERNANDEZ, A. V., & KATTAN, M. W. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.6.431 · Cited by 519 · cited 1×
“Fourth, the reporting of less common infection-related adverse events varied considerably across RCTs, potentially introducing selective outcome reporting bias [29, 30].”
BackgroundZaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 489
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.560181 · Cited by 287
Cited by
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
“The frequency of UTIs was not significantly increased with SGLT2i versus either DPP4i or GLP1-RA in two studies [144,145].”
BackgroundResultInfluentialErectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
Taylor, S. I., Blau, J. E., Rother, K. I., & Beitelshees, A. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30154-8 · Cited by 124
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab274 · Cited by 97
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Sodium glucose co-transporter 2 inhibitors and heart failure.
Ghosh, R. K., Ghosh, G. C., Gupta, M., Bandyopadhyay, D., Akhtar, T., Deedwania, P., Lavie, C. J., Fonarow, G. C., & Aneja, A. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.08.038 · Cited by 41
Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01103-9 · Cited by 39
Wang, C., Zhou, Y., Kong, Z., Wang, X., Lv, W., Geng, Z., & Wang, Y. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13620 · Cited by 39
Sarafidis, P. A., & Ortiz, A. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfz170 · Cited by 37
“These results are strengthened by a recent metaanalysis including data from 86 randomized clinical trials with 50 880 patients [18].”
ResultShi, F.-H., Li, H., Shen, L., Zhang, Z., Jiang, Y.-H., Hu, Y.-M., Liu, X.-Y., Gu, Z.-C., Ma, J., & Lin, H.-W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01066 · Cited by 30
Rao, L., Ren, C., Luo, S., Huang, C., & Li, X. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01686-x · Cited by 29
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Metadata
- Authors
- Puckrin, R., Saltiel, M.-P., Reynier, P., Azoulay, L., Yu, O. H. Y., & Filion, K. B.
- Venue
- Acta Diabetologica
- Published
- 2018-02-27
- Volume
- 55
- Issue
- 5
- Pages
- 503-514
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2790579026
- Cited by
- 278
- References
- 26
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.